Monoclonal Antibody to the Amyloid B Peptide

Stony Brook University is actively seeking companies interested in licensing a high affinity antibody developed to bind the amyloid β peptide mAb 20.1 for possible use as therapeutic agents with Alzheimer’s and central nervous amyloid diseases.

**Technology Description:**
Aβ forms the senile plaques and cerebrovascular deposits thought to contribute to the onset of Alzheimer’s disease. Each of these antibodies developed by William E. Van Nostrand, Ph. D., professor in the Department of Medicine at Stony Brook University, binds to the N-terminal region of Aβ peptide with high affinity. Use of the 20.1 antibody in passive immunization of mouse models of Alzheimer’s disease has resulted in clearance of Aβ peptides from the brain. Moreover, similar antibodies of this type have been shown to block and break down amyloid plaque formation. These antibodies can be studied for viability as therapeutic agents.

**Applications:**
These antibodies also are useful for analysis of Aβ in methodologies such as:
- ELISA
- Immunoblot
- Immunohistochemistry
- Immunoprecipitation

**Publications:**
- Localization Of A Fibrillar Amyloid Beta-Protein Binding Domain On Its Precursor.

Adam M. DeRosa, Ph. D.
Licensing Associate
Office of Technology Licensing & Industry Relations
N5002 Melville Library
Stony Brook University
Stony Brook, NY 11794-3369
631-632-6956 (voice)
631-632-1505 (fax)
Adam.DeRosa@stonybrook.edu
www.stonybrook.edu/research/otlr